HBC recorded total operating revenues of NOK 83.5 million in the third quarter of 2026, compared to NOK 54.9 million in the same period last year, which is the highest quarterly revenue HBC has recorded. Net operating revenues were NOK 82.1 million, up from NOK 54.8 million in Q3 2025.
EBITDA for the quarter was positive NOK 4.4 million, compared to negative NOK 21.1 million in Q3 2025. The Operational EBITDA* amounted to NOK 10.3 million (negative NOK 12.9 million in Q3 2025), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs.
The operating result (EBIT) was negative NOK 5.7 million (-30.6) in the last quarter. Cash and cash equivalents decreased by NOK 80.6 million during the quarter, ending at NOK 33.6 million as of 30 September 2026 (65.5). Including available credit facilities, total liquidity was NOK 42.5 million at quarter-end (67.0).
Highlights in the third quarter:
Please find the HBC Q3 2026 Financial report attached.
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry, taking fresh filleted salmon and converting it from a waste product into ingredients to improve human and pet health. These ingredients are ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil containing all the fatty acid fractions found in fish; and CalGo®/NT-II® salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health.
HBC places scientific evidence at the forefront, which has led to important academic partnerships and the identification of unique health benefits. HBC is listed on Oslo Stock Exchange with ticker “HBC”.
*) Alternative Performance Measures are further described on page 11 in the financial report.
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Attachment
